Loading clinical trials...

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome | Clinical Trials | Clareo Health

WITHDRAWNPHASE2

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

Phase II Trial of Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 ARDS - A Multi-Site, Randomized, Double-blinded, Placebo-Controlled Clinical Trial

NCT04725110•University of Minnesota

View on ClinicalTrials.gov

Summary

Acute treatment of COVID-ARDS with direct topical lung instilled T3 therapy for patients on mechanical ventilation.

Detailed Description

Post-hospitalization follow-up for 6 and 12-months of survival and end-organ dysfunction (lung, heart, kidney, neuropsychological), plus quality of life and return to work of those previously working

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of SARS-CoV-2 with first positive test within 14 days, and,
•Diagnosis of ARDS by the Berlin Criteria (2012):
•1. Onset: \< 7 days
•2. Chest x-ray: Bilateral Patchy Opacities, Infiltrates
•3. Mechanical Vent Support: PEEP or CPAP Support \>= 5 cm H2O
•4. Pulmonary Edema: Not fully explained by cardiogenic etiology
•5. Hypoxia: PaO2/FIO2 Ratio \< 300, or O2Sat/FIO2 Ratio \< 315

Exclusion Criteria

•Pregnancy

Locations (1)

University of Minnesota

Minneapolis, Minnesota, United States

Key Dates

Start Date

January 15, 2026

Primary Completion Date

October 15, 2030

Completion Date

October 15, 2031

Last Updated

February 10, 2026

Conditions

Covid19SARS-CoV InfectionARDSARDS, Human

Interventions

Instilled T3

DRUG

Placebo Therapy

OTHER

Turning Ratios Into Prognosis: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients: A Prospective Evaluation

NCT07414056

Acute Respiratory Distress Syndrome (ARDS)

View study

RECRUITINGPHASE2

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

NCT06701669

Acute Respiratory Distress Syndrome (ARDS)ARDS+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 10, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

Inclusion Criteria

Exclusion Criteria

Turning Ratios Into Prognosis: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients: A Prospective Evaluation

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

Diagnostic Stewardship Intervention to Reduce Inappropriate Antibiotic Use for Urinary Tract Infections in Primary Care

STimulation to Activate RespIration

High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS

Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury